Funding for this research was provided by:
Instituto de Salud Carlos III (CP14/00229)
European Research Council (810287)
Horizon 2020 Framework Programme (SEP-210574908)
Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P)
Received: 7 January 2020
Accepted: 28 April 2020
First Online: 11 May 2020
Ethics approval and consent to participate
: The enrolled CLL patients gave informed consent for this study following the ICGC guidelines and the ICGC Ethics and Policy committee. This study was approved by the clinical research ethics committee of the Hospital Clínic of Barcelona. For healthy PBMC donors, the study was approved by the local ethics committee, and all the patients signed an informed consent. This study was conducted in accordance with the Declaration of Helsinki principles.
: The authors declare no conflict of interest.